Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cance

Carcinogenesis

Volumn 36, Issue 12, 2015, Pages 1561-1571

  Bae, Taejeong ^a   Weon, Kwon Yeon ^b   Lee, Jeong Won ^c,d   Eum, Ki Hwan ^e   Kim, Sungchul ^e   Choi, Jin Woo ^e,f  

^a MAYO CLINIC   (United States)

^b Catholic University of Daegu   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Wonkwang University   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALSTERPAULLONE; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; INDOLE DERIVATIVE; PACLITAXEL;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAZEPINES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; MICE, INBRED C57BL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949789202     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv14     Document Type: Article

References (46)

1. Agarwal, R. et al. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer, 3, 502-516.
2. Abdullah, L.N. et al. (2013) Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med., 2, 3.
3. Ali, A.Y. et al. (2012) Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. N. Y. Acad. Sci., 1271, 58-67.
4. Saraswathy, M. et al. (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol. Adv., 31, 1397-1407.
5. Dasari, S. et al. (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol., 740, 364-378.
6. Kim, A. et al. (2012) Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res., 31, 14
7. Shen, D.W. et al. (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev., 64, 706-721.
8. Jordan, M.A. et al. (2004) Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 4, 253-265.
9. Milross, C.G. et al. (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst., 88, 1308-1314.
10. Sugimura, M. et al. (2004) Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Oncology, 66, 53-61.
11. Greenberger, L.M. et al. (1988) Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc. Natl. Acad. Sci. USA, 85, 3762-3766.
12. Orr, G.A. et al. (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene, 22, 7280-7295.
13. Parekh, H. et al. (1997) Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol., 53, 461-470.
14. Kavallaris, M. et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest., 100, 1282-1293.
15. Lim, S. et al. (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 140, 3079-3093.
16. Castedo, M. et al. (2002) Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ., 9, 1287-1293.
17. Monaco, E.A. 3rd et al. (2003) Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr. Med. Chem., 10, 367-379.
18. Monaco, E.A. 3rd et al. (2005) Role of protein kinases in neurodegenerative disease: cyclin-dependent kinases in Alzheimer's disease. Front. Biosci., 10, 143-159.
19. Diril, M.K. et al. (2012) Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc. Natl. Acad. Sci. USA, 109, 3826-3831.
20. Shapiro, G.I. (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 24, 1770-1783.
21. Cui, C. et al. (2013) Alsterpaullone, a cyclin-dependent kinase inhibitor, mediated toxicity in HeLa cells through apoptosis-inducing effect. J. Anal. Methods Chem., 2013, 602091.
22. Leost, M. et al. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem., 267, 5983-5994.
23. Brault, L. et al. (2005) New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. Eur. J. Med. Chem., 40, 757-763.
24. Blakey, J.D. et al. (2011) Current progress in pharmacogenetics. Br. J. Clin. Pharmacol., 71, 824-831.
25. Lamb, J. et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 313, 1929-1935.
26. Wei, G. et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 10, 331-342.
27. Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA, 102, 15545-15550.
28. Carro, M.S. et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature, 463, 318-325.
29. Choi, J.W. et al. (2011) Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet., 7, e1001351.
30. Choi, C.H. et al. (2012) Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br. J. Cancer, 107, 91-99.
31. Cormio, G. et al. (2011) Long-term topotecan therapy in recurrent or persistent ovarian cancer. Eur. J. Gynaecol. Oncol., 32, 153-155.
32. Hyman, D.M. et al. (2011) Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol. Oncol., 123, 196-199.
33. Te, A.E. (2002) A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clin. Ther., 24, 851-861; discussion
34. Sawada, S. et al. (2003) Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatinresistant human epidermoid carcinoma cell line. Cancer Chemother. Pharmacol., 51, 505-511.
35. Yamamoto, K. et al. (2000) Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J. Cancer Res. Clin. Oncol., 126, 168-172.
36. Sherr, C.J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
37. Kastan, M.B. et al. (2004) Cell-cycle checkpoints and cancer. Nature, 432, 316-323.
38. Harley, M.E. et al. (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J., 29, 2407-2420.
39. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
40. Malumbres, M. et al. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153-166.
41. Santamaría, D. et al. (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature, 448, 811-815.
42. Zieve, G.W. et al. (1980) Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp. Cell Res., 126, 397-405.
43. Androic, I. et al. (2008) Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer, 8,
44. Henley, D. et al. (2007) Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother. Pharmacol., 59, 235-249.
45. Sausville, E.A. et al. (2000) Inhibition of CDKs as a therapeutic modality. Ann. N. Y. Acad. Sci., 910, 207-221; discussion
46. Soni, D.V. et al. (2004) Inhibition of cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G2 through prophase. Cell Cycle, 3, 349-357.